Bill
Bill > A00425
NY A00425
NY A00425Requires health insurance policies to cover comprehensive genetic screening and FDA approved biomarker testing for ovarian and prostate cancers.
summary
Introduced
01/06/2021
01/06/2021
In Committee
01/05/2022
01/05/2022
Crossed Over
Passed
Dead
12/31/2022
12/31/2022
Introduced Session
2021-2022 General Assembly
Bill Summary
AN ACT to amend the insurance law, in relation to requiring health insurance policies to fully cover comprehensive genetic testing and FDA approved biomarker testing for ovarian and prostate cancers
AI Summary
This bill requires health insurance policies in New York to fully cover comprehensive genetic testing and FDA-approved biomarker testing for ovarian and prostate cancers. The coverage applies when recommended by a doctor, board-certified geneticist, or board-certified genetic counselor, and also after a patient's initial diagnosis. The genetic results cannot be used to deny insurance coverage to family members who carry the same genetic or inherited mutation. All costs associated with this additional coverage must be borne solely by the insurer and are not subject to annual deductibles or coinsurance.
Committee Categories
Business and Industry
Sponsors (14)
Brian Barnwell (D)*,
Aileen Gunther (D)*,
N. Nick Perry (D)*,
José Rivera (D)*,
Nily Rozic (D)*,
Thomas Abinanti (D),
Jeffrion Aubry (D),
Harry Bronson (D),
William Colton (D),
Vivian Cook (D),
Danny O'Donnell (D),
Steve Otis (D),
Jo Anne Simon (D),
David Weprin (D),
Last Action
print number 425a (on 01/27/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...